To hear about similar clinical trials, please enter your email below
Trial Title:
Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)
NCT ID:
NCT02156362
Condition:
Thyroid Cancer
Conditions: Official terms:
Carcinoma
Thyroid Neoplasms
Thyroid Diseases
Conditions: Keywords:
Thyroid carcinoma
predictive factors
refractory
Differentiated
follicular origin
Study type:
Interventional
Study phase:
N/A
Overall status:
Unknown status
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Other
Masking:
None (Open Label)
Intervention:
Intervention type:
Other
Intervention name:
follow up visit
Description:
At least 1 follow up visit per year will be done and an additional visit if needed.
Arm group label:
follow up
Summary:
It is generally estimated that 5 % of patients with thyroid cancer will develop distant
metastases, and most of them had an advanced stage of the disease at presentation. Thirty
per cent of them are resistant to radio iodine therapy and are called "refractory". Their
long term survival is estimated to be less than 10 %.
The objective of this study is to identify the factors associated with poor outcome in a
cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and
medullary thyroid carcinomas were excluded.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Man or woman ≥ 18 years.
- Thyroid cancer differentiated from follicular origins (papillary, vesicular or
poorly differentiated carcinoma).
- TNM classification: stage pT3 (≥2 cm), or pT4 or M1 at diagnosis.
- Patient after post operative radioiodine therapy.
Exclusion Criteria:
- Patient who can not be followed during the protocol.
- Patient who does not consent.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Hospices Civils de Lyon-Centre de Médecine Nucléaire Groupement Hospitalier Est 59 boulevard Pinel
Address:
City:
Bron cedex
Zip:
69677
Country:
France
Start date:
May 2012
Completion date:
May 2023
Lead sponsor:
Agency:
Hospices Civils de Lyon
Agency class:
Other
Source:
Hospices Civils de Lyon
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT02156362
